Postmenopausal Osteoporosis Market - Growth, Trends, and Forecasts (2(2023 - 2028)

The postmenopausal osteoporosis market is projected to register a CAGR of 3.9% during the forecast period of 2022-2027.

The outbreak of COVID-19 has significantly impacted the healthcare industry, including relative negligence of chronic diseases such as osteoporosis. A survey conducted by the National Osteoporosis Foundation and International Osteoporosis Foundation concluded that the major impact includes delays in scanning for diagnosis, interruptions in the supply of drugs and raw material, an increase in telemedicine consultations, and a decrease in parenteral medicine delivery. Further, according to a research study published in March 2021, titled "Effects of COVID-19 Lockdown on Adherence to Individual Home- or Gym-Based Exercise Training among Women with Postmenopausal Osteoporosis", being at home can result in decreased physical activity and sedentary behavior, the COVID-19 epidemic and its constraints may have interfered with the study participants' schedules and motivation, and the reduction or lack of social bonds that are usually essential to encourage the elderly to exercise may have reduced. Hence, COVID-19 is expected to have a significant impact on the postmenopausal osteoporosis market, however, with the decreasing COVID-19 cases and large-scale vaccination programs, the studied market is expected to regain its full potential over the forecast period.

The aging population and lifestyle changes are the key factors responsible for the growth of the postmenopausal osteoporosis market as the older population is more prone to osteoporosis and thus increase in their population is expected to be a significant growth factor. For instance, according to the World Health Organization's October 2021 report, the population of people of age 60 years and more is expected to increase from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. Hence, the market is projected to grow during the forecast period with an increase in demand for therapy of postmenopausal osteoporosis in the older population.

Additionally, lifestyle changes such as lack of exercise, high consumption of alcohol or smoking, prolonged work duration, and unhealthy eating habits also impact the menopausal period and lead to osteoporosis in many women worldwide. Age, smoking, alcohol, and consumption of medications used to treat various diseases such as gonadotropins, excess consumption of thyroid hormone, and cytotoxic agents are some of the risk factors for causing low bone density and thereby developing osteoporosis after menopause in women. According to data published by the International Menopause Society (IMS), in 2021, more than 200 million women are estimated to suffer from osteoporosis, and 1 in 3 women aged more than 50 is expected to experience osteoporosis fracture. Therefore, due to the aforementioned factors, the studied market is expected to grow over the forecast period. However, low awareness about postmenopausal osteoporosis is expected to restrain the growth of the studied market during the forecast period.

Postmenopausal Osteoporosis Market Trends

The Bisphosphonates Segment is Expected to Hold Largest Share in the Postmenopausal Osteoporosis Market Over Forecast Period

The bisphosphonates class of drug is expected to be accounted for the market's maximum share, which can be attributed to their ability to prevent the loss of bone density and thereby minimize the fracture risk by 50%. Additionally, bisphosphonates can be tolerated by most patients on a long-term basis. For instance, according to an article published in April 2021, titled "Bisphosphonate Medications for Osteoporosis: Concerns Regarding Risks and Side Effects", by inhibiting osteoclast activity, bisphosphonates reduce bone resorption and numerous studies have demonstrated that this family of drugs can increase bone density and lower fracture risk in those with low bone density. Hence, they are prescribed widely for most patients with osteoporosis and thus expected to have a significant share in the studied market.

Alendronate, risedronate, ibandronate, and zoledronic acid are some of the most prescribed bisphosphonates to prevent and treat postmenopausal osteoporosis. A new regimen through the intravenous route is under investigation, and positive results from the trial can further accelerate the market of bisphosphonates during the forecast period. Bisphosphonates are generally prescribed for five years, and the bone-protective benefit of the drug continues even after the treatment discontinuation. Therefore, owing to the above-mentioned factors, the bisphosphate segment is expected to have a significant market share in the postmenopausal osteoporosis market.

North America Region is Expected to Occupy a Significant Share in the Postmenopausal Osteoporosis Market

North America contributes the highest revenue in the market due to its developed healthcare infrastructure, presence of major industry players, high diagnosis and treatment rate, more patient compliance, and large patient base. The United States contributes the maximum share in North America. According to the data published by the Centers for Disease Control and Prevention (CDC) in 2021, about 18.8% of women aged 50 years or more had osteoporosis. The prevalence is expected to increase further due to sedentary lifestyles and unhealthy eating & drinking habits. According to the National Osteoporosis Foundation, it is projected that by 2030, about 71 million Americans will have osteoporosis and low bone mass condition.

High research and development activities due to investment by market players and research institutes are expected to further accelerate the market growth during the forecast period from 2022 to 2027. According to data published on clinicaltrial.gov as of June 2021, about 25 active Phase III and Phase IV clinical trials are going on in the United States for osteoporosis drugs. Also, as per the May 2022 update of the National Institute of Health of the United States, about USD 155 million in funding is allocated for osteoporosis in 2021, an increase of USD 7 million from the previous years, and this funding are further expected to have a positive impact on the studied market. Therefore, due to the above-mentioned factors, the postmenopausal osteoporosis market is expected to grow in the North American region over the forecast period.

Postmenopausal Osteoporosis Market Competitor Analysis

The postmenopausal osteoporosis market is fragmented and competitive due to several generics in the market. However, some of the key players operating in the market are Novartis International AG, Eli Lilly and CO., Pfizer Inc., Merck & Co., Inc., BiologicsMD, AbbVie (Allergan plc.), and Cipla Inc. Increasing awareness about postmenopausal osteoporosis, developing new drugs, and partnerships or collaborations to reach their drugs at maximum patients are some strategies market players are utilizing to gain market share in the industry.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support